Presentation is loading. Please wait.

Presentation is loading. Please wait.

Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing.

Similar presentations


Presentation on theme: "Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing."— Presentation transcript:

1 Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee  J.J. Cherian, J. Parvizi, D. Bramlet, K.H. Lee, D.W. Romness, M.A. Mont  Osteoarthritis and Cartilage  Volume 23, Issue 12, Pages (December 2015) DOI: /j.joca Copyright © 2015 Osteoarthritis Research Society International Terms and Conditions

2 Fig. 1 Enrollment flowchart.
Osteoarthritis and Cartilage  , DOI: ( /j.joca ) Copyright © 2015 Osteoarthritis Research Society International Terms and Conditions

3 Fig. 2 Mean IKDC subjective knee evaluation scores over time by treatment group. Osteoarthritis and Cartilage  , DOI: ( /j.joca ) Copyright © 2015 Osteoarthritis Research Society International Terms and Conditions

4 Fig. 3 Mean VAS pain scores over time by treatment group.
Osteoarthritis and Cartilage  , DOI: ( /j.joca ) Copyright © 2015 Osteoarthritis Research Society International Terms and Conditions


Download ppt "Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing."

Similar presentations


Ads by Google